A cash-pay homocysteine blood test costs between $69.00 and $81.00 at retail direct-to-consumer services, and whether insurance covers the draw depends almost entirely on the diagnosis code attached to the order. At Longevity Benchmark, we track diagnostic pricing and laboratory coverage policies to clarify what consumers pay out of pocket before completing blood work.
The Verdict
Cash Prices at Direct-to-Consumer Laboratories
Retail pricing for an upfront, cash-pay homocysteine blood test ranged from $69.00 to $81.00 across consumer testing platforms when checked on October 7, 2026. Because direct retail rates change over time, individuals should confirm current figures on the provider websites before scheduling a draw.
On October 7, 2026, Labcorp OnDemand listed its standalone Homocysteine Test at $79.00. The consumer testing branch of Quest Diagnostics listed its standalone test at $75.00 plus an additional $6.00 Physician Service Fee, establishing an actual checkout total of $81.00. Third-party requisition broker Walk-In Lab advertised a regular list price of $69.00 for a test processed at partner Quest or Labcorp patient service centers.
| Laboratory Service | Verified Cash Price (October 7, 2026) | Pricing Details |
|---|---|---|
| Walk-In Lab | $69.00 | Published regular list price for an order routed to Labcorp or Quest facilities. |
| Labcorp OnDemand | $79.00 | Direct consumer purchase price listed for the standalone Homocysteine Test. |
| Quest Diagnostics | $81.00 | Total checkout cost combining the $75.00 test charge with the mandatory $6.00 Physician Service Fee. |
CPT Code 83090 and Laboratory Billing Details
The standard Current Procedural Terminology code identifying a quantitative homocysteine blood test is CPT 83090. This five-digit billing identifier is confirmed across independent laboratory documentation, including the Labcorp test directory (test 706994), the published product listing at Walk-In Lab, and Medicare policy documentation.
Quoting CPT 83090 allows patients to verify local out-of-pocket pricing directly with medical billing offices or clinical laboratories before an appointment. Stating the specific billing code removes naming ambiguities, as laboratories offer multiple cardiovascular panels and nutrient assays. Medicare's paid amount for 83090 is not stated here.
Medicare Local Coverage Determination L34419 Rules
Medicare coverage for homocysteine testing is governed by strict medical necessity criteria outlined in regional contractor determinations. For jurisdiction JM, managed by Palmetto GBA, Local Coverage Determination (LCD) L34419 establishes explicit coverage allowances and coverage exclusions, as reproduced in the Quest Diagnostics Medicare Local Coverage Policy reference for CPT 83090.
According to LCD L34419, serum homocysteine levels are covered to confirm vitamin B12 or folate deficiency. In contrast, when requested for cardiovascular evaluation, the policy states that in the absence of evidence that treatment of hyperhomocysteinemia reduces cardiovascular events, testing is covered only in patients with known vascular disease or risk thereof (based upon abnormal lipid metabolism, high blood pressure, or diabetes mellitus) for the purpose of risk stratification, and in that circumstance it will be covered only once per lifetime.
The policy explicitly excludes routine screening and ongoing cardiovascular monitoring. LCD L34419 notes that when used to determine the risk of developing atherosclerotic cardiovascular disease in the absence of known vascular disease, hyperlipidemia, or diabetes mellitus, the test will be denied as screening. The document further states that serum homocysteine measurement to evaluate the treatment of hyperhomocysteinemia in patients with cardiovascular risk factors will be denied as not medically necessary, citing the HOPE-2 and NORVIT clinical trials to support the rationale that vitamin supplementation has not demonstrated reductions in cardiovascular event risks. Other regional Medicare contractors maintain their own contractor policies, so beneficiaries should confirm local rules.
Commercial Coverage Criteria in Aetna Clinical Policy Bulletin 0763
Commercial insurer coverage policies also draw sharp distinctions based on the underlying diagnosis code. In Aetna Clinical Policy Bulletin 0763, titled Homocysteine Testing, Aetna lists specific clinical conditions for which testing is considered medically necessary, while designating other uses as experimental, investigational, or unproven.
Aetna considers homocysteine testing medically necessary for evaluating borderline vitamin B12 deficiency where results alter clinical management, assessing homocystinuria caused by cystathionine beta synthase deficiency, evaluating idiopathic or recurrent venous thromboembolism, assessing thrombosis occurring at a young age (under 45 years), evaluating thrombosis at an unusual anatomical site, and assessing central retinal vein occlusion under specified clinical conditions.
Conversely, Aetna CPB 0763 explicitly classifies testing as experimental, investigational, or unproven for the assessment of cardiovascular disease or stroke risk. Aetna also designates testing as experimental for recurrent pregnancy loss, pre-eclampsia, Alzheimer's disease diagnosis, erectile dysfunction progression, gastric cancer risk, multiple sclerosis evaluation, and polycystic ovary syndrome management. Because Aetna is a single commercial payer, individuals enrolled in other commercial health plans must check their plan documents directly to determine how their insurer evaluates CPT 83090.
Routine Screening Compared to Diagnostic Workup
National public health references clarify that general cardiovascular screening using homocysteine is not recommended for asymptomatic populations. The official MedlinePlus medical test overview states that routine homocysteine testing to screen for heart disease risk is not recommended for everyone, noting that the test is most often used to measure vitamin B6, B12, and folic acid levels.
This diagnostic distinction explains why testing ordered for general cardiovascular curiosity or broad wellness assessments often results in claim denials. Patients exploring vascular risk markers can review our guide to ApoB blood test cost to examine how other cardiovascular tests are priced. Those investigating nutritional status can read about the vitamin B12 test and clinical signs of vitamin B12 deficiency for guidance on standard metabolic pathways.
Specimen Collection and Fasting Preferences
Laboratory preparation instructions for homocysteine testing vary by facility. According to the Labcorp test directory entry for test 706994, a fasting specimen is preferred to establish baseline values or monitor treatment. Labcorp does not publish an exact hourly fasting duration in that document.
Labcorp states that a fasting specimen is preferred to establish baseline values or monitor treatment. Those considering remote testing can review our analysis of at-home blood test accuracy to understand how collection methods compare with standard in-clinic venous phlebotomy.
Financial Considerations for Cash versus Insurance Routing
Deciding between self-paying or submitting a claim through health insurance depends on the indication for the test. Medicare LCD L34419 names suspected vitamin B12 or folate deficiency, and risk stratification in patients with known vascular disease, hyperlipidemia or diabetes. Aetna CPB 0763 names borderline B12 deficiency, homocystinuria, and specified thrombotic presentations.
If the test is requested purely for preventative health tracking or longevity optimization, billing insurance creates a substantial risk of claim denial. When an insurer denies coverage for non-qualifying diagnoses, the patient becomes responsible for the facility's billed charges. Paying an upfront cash price of $69.00 to $81.00 provides total cost predictability before the blood draw occurs. For further context on baseline figures across demographics, refer to our reference on homocysteine levels by age and our overview of homocysteine testing.
Frequently Asked Questions
How much does a homocysteine test cost out of pocket?
A standalone cash-pay homocysteine blood test costs between $69.00 and $81.00 at major consumer testing platforms, verified on October 7, 2026. Walk-In Lab listed a regular price of $69.00 for testing drawn at Quest or Labcorp locations, Labcorp OnDemand listed its standalone test at $79.00, and Quest Diagnostics listed a $75.00 test fee plus a $6.00 Physician Service Fee for an $81.00 total. Direct cash prices fluctuate over time, so patients should confirm final pricing on the vendor websites before ordering.
Is a homocysteine blood test covered by Medicare?
Medicare coverage depends on the specific medical diagnosis provided with the order. Under regional contractor Palmetto GBA Local Coverage Determination L34419, Medicare covers serum homocysteine testing to confirm vitamin B12 or folate deficiency. For cardiovascular risk stratification in individuals with established vascular disease or specific risk factors like diabetes or hypertension, it is covered only once per lifetime, while routine cardiovascular screening and treatment monitoring are explicitly denied. Coverage guidelines can vary across regional Medicare contractors.
Does private health insurance cover a homocysteine test?
Coverage among private insurers depends on individual plan benefits and the medical justification for the order. For example, Aetna Clinical Policy Bulletin 0763 considers homocysteine testing medically necessary for borderline vitamin B12 deficiency, homocystinuria, and specific venous thromboembolic disorders, but designates testing for cardiovascular disease or stroke risk as experimental and investigational. Because commercial policies differ across carriers, members must contact their specific insurer to verify coverage criteria for CPT 83090.
What is the CPT code for a homocysteine test?
The billing code for a quantitative homocysteine blood test is CPT 83090. This code is verified in the Labcorp test directory, Walk-In Lab documentation, and Medicare Local Coverage Determination L34419. Patients can provide this five-digit code to insurance customer service representatives or clinical billing departments to obtain specific coverage determinations and out-of-pocket estimates before their blood draw.
Do I need to fast before a homocysteine blood test?
Preparation requirements depend on the processing facility. According to the Labcorp test directory for test 706994, a fasting specimen is preferred to establish baseline values or monitor treatment. Labcorp does not publish a mandatory hourly fasting window in that catalog listing. Patients should confirm specific fasting expectations directly with the ordering clinician or their scheduled laboratory draw site.
Why do insurance policies deny homocysteine tests for cardiovascular screening?
Aetna and Medicare both restrict cardiovascular screening because clinical trials have not demonstrated improved patient outcomes from homocysteine-lowering therapies. In Medicare LCD L34419, Palmetto GBA notes that clinical studies, specifically citing the HOPE-2 and NORVIT trials, have failed to show that vitamin supplementation lowering serum homocysteine reduces cardiovascular or cerebrovascular event risks. Similarly, Aetna Clinical Policy Bulletin 0763 classifies cardiovascular disease risk assessment using homocysteine as experimental and unproven.
Can I order a homocysteine blood test without a doctor?
Yes, direct-to-consumer services such as Labcorp OnDemand, Quest Diagnostics, and Walk-In Lab permit individuals to purchase a homocysteine test online without visiting their personal physician. These platforms utilize affiliated physician networks to authorize the laboratory requisition. However, self-ordered laboratory results arrive without clinical context, requiring consumers to consult a qualified healthcare provider for medical interpretation.
What conditions are accepted as medically necessary for homocysteine testing?
Documented medical necessity generally focuses on metabolic and hematologic conditions rather than general wellness. For example, Aetna CPB 0763 designates testing as medically necessary for assessing borderline vitamin B12 deficiency, homocystinuria from cystathionine beta synthase deficiency, and specific idiopathic or early-onset venous thromboembolisms. Medicare LCD L34419 covers testing to confirm vitamin B12 or folate deficiency, as well as a single lifetime test for cardiovascular risk stratification in patients with documented vascular disease or qualifying risk factors.